BRPI0514519A - uso de xenÈnio como neuroprotetor em um indivìduo neonatal - Google Patents

uso de xenÈnio como neuroprotetor em um indivìduo neonatal

Info

Publication number
BRPI0514519A
BRPI0514519A BRPI0514519-8A BRPI0514519A BRPI0514519A BR PI0514519 A BRPI0514519 A BR PI0514519A BR PI0514519 A BRPI0514519 A BR PI0514519A BR PI0514519 A BRPI0514519 A BR PI0514519A
Authority
BR
Brazil
Prior art keywords
xenon
neonatal
neuroprotective agent
individual
neonatal individual
Prior art date
Application number
BRPI0514519-8A
Other languages
English (en)
Inventor
Nicholas Peter Franks
Mervyn Maze
Original Assignee
Protexeon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protexeon Ltd filed Critical Protexeon Ltd
Publication of BRPI0514519A publication Critical patent/BRPI0514519A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

USO DE XENÈNIO COMO NEUROPROTETOR EM UM INDIVìDUO NEONATAL presente invenção diz respeito ao uso de xenónio na preparação de um medicamento para impedir e/ou aliviar um ou mais déficits neurológicos induzidos por anestésica em um indivíduo neonatal. A presente invenção também diz respeito às combinações de xenónio e sevoflurano, e uso destes cama agentes de pré-condicionamento para administração antes de lesão hipóxico-isquêmica.
BRPI0514519-8A 2004-08-19 2005-08-19 uso de xenÈnio como neuroprotetor em um indivìduo neonatal BRPI0514519A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0418540.1A GB0418540D0 (en) 2004-08-19 2004-08-19 Use
PCT/GB2005/003253 WO2006018655A1 (en) 2004-08-19 2005-08-19 Use of xenon as neuroprotectant in a neonatal subject

Publications (1)

Publication Number Publication Date
BRPI0514519A true BRPI0514519A (pt) 2008-06-10

Family

ID=33042333

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514519-8A BRPI0514519A (pt) 2004-08-19 2005-08-19 uso de xenÈnio como neuroprotetor em um indivìduo neonatal

Country Status (13)

Country Link
US (2) US20090311340A1 (pt)
EP (1) EP1778256B1 (pt)
JP (1) JP5175097B2 (pt)
AU (1) AU2005273641B2 (pt)
BR (1) BRPI0514519A (pt)
CA (2) CA2576156C (pt)
DK (1) DK1778256T3 (pt)
ES (1) ES2674347T3 (pt)
GB (1) GB0418540D0 (pt)
MX (1) MX2007001822A (pt)
PL (1) PL1778256T3 (pt)
PT (1) PT1778256T (pt)
WO (1) WO2006018655A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1830856B1 (en) * 2004-08-02 2012-04-18 John W. Olney Preventing pathological increases in the rate of nerve cell suicide in immature nervous systems
EP1980261A1 (en) 2007-04-10 2008-10-15 Nicholas Peter Franks Use of helium with oxygen to provide neuroprotection
EP1980260A1 (en) 2007-04-10 2008-10-15 Nicholas Peter Franks Use of hyperbaric conditions to provide neuroprotection
RU2583179C2 (ru) 2011-02-07 2016-05-10 ЭДВАНСТ ПРЕЗЕРВЕЙШНЗ ТЕКНОЛОДЖИЗ, ЭлЭлСи Способ консервации клеток и культур клеток
CA2860037C (en) 2011-09-26 2019-09-24 Advanced Preservations Technologies, Llc Method for living tissue preservation
CN110464709A (zh) * 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
WO2014145443A2 (en) 2013-03-15 2014-09-18 The Board Of Regents Of The University Of Texas System Liquids rich in noble gas and methods of their preparation and use
WO2015024100A1 (en) * 2013-08-19 2015-02-26 Schmidt Klaus Michael Non-anesthetic protective gases in combination with liquid anesthetic agents for organ protection
FR3021220B1 (fr) * 2014-05-21 2017-08-25 Air Liquide Association de xenon et d’un antioxydant pour lutter contre une maladie neurodegenerative de type maladie de parkinson
US10828436B2 (en) * 2016-04-05 2020-11-10 Vanderbilt University Administering the noble gas argon during cardiopulmonary resuscitation
CN112805038A (zh) * 2018-07-18 2021-05-14 悦智有限公司 用于使化合物加速组织穿透到脑内的方法
WO2020150698A1 (en) * 2019-01-18 2020-07-23 The Johns Hopkins University Prevention of anesthetic-induced neurocognitive dysfunction
US12599625B2 (en) 2021-05-13 2026-04-14 Penland Foundation Treatment of ARDS and other conditions caused by acutely elevated cytokine levels and post ARDS chronic cytokine production using inhaled anesthetics
WO2023287726A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of cancer using botulinum toxin and nitrous oxide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19933704A1 (de) * 1999-07-19 2001-01-25 Michael Georgieff Verwendung einer lipophile Gase enthaltenden Präparation zur Neuroprotektion und Neuroregeneration
US6653354B2 (en) * 1999-07-29 2003-11-25 Protexeon Limited NMDA antagonist comprising xenon
DE10045829A1 (de) * 2000-09-14 2002-04-04 Messer Griesheim Gmbh Volatile Anästhesiemittel mit Xenon
GB0209998D0 (en) 2002-05-01 2002-06-12 Protexeon Ltd Use
GB0218153D0 (en) * 2002-08-05 2002-09-11 Ic Innovations Ltd An analgesic agent for newborn or retal subjects
CA2538104C (en) 2003-10-10 2013-12-10 Protexeon Limited Use of xenon with hypothermia for treating neonatal asphyxia

Also Published As

Publication number Publication date
AU2005273641B2 (en) 2011-10-20
JP5175097B2 (ja) 2013-04-03
ES2674347T3 (es) 2018-06-29
PL1778256T4 (pl) 2018-09-28
JP2008509981A (ja) 2008-04-03
WO2006018655A1 (en) 2006-02-23
CA2781626C (en) 2016-07-05
US20090311340A1 (en) 2009-12-17
EP1778256B1 (en) 2018-03-21
US9326996B2 (en) 2016-05-03
MX2007001822A (es) 2007-10-10
CA2576156A1 (en) 2006-02-23
EP1778256A1 (en) 2007-05-02
AU2005273641A1 (en) 2006-02-23
PL1778256T3 (pl) 2018-09-28
DK1778256T3 (en) 2018-07-02
CA2576156C (en) 2013-11-12
US20150216897A1 (en) 2015-08-06
PT1778256T (pt) 2018-07-25
CA2781626A1 (en) 2006-02-23
GB0418540D0 (en) 2004-09-22

Similar Documents

Publication Publication Date Title
AR022886A1 (es) Utilizacion de xenon o mezclas de gas xenon composicion para el tratamiento de intoxicaciones neurologicas y procedimiento para la preparacion de un medicamento inhalable
CR9748A (es) Derivados de xantina como agonistas selectivos de hm74a
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
CL2007002752A1 (es) Compuestos derivados de 3-(4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar o prevenir enfermedades tales como cancer, dolor, degeneracion macular, trastorno pulmonar, tr
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
CL2007001427A1 (es) Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
UY31570A1 (es) Derivados de oxadiazol agonistas del receptor s1p1. composiciones farmacéuticas que lo comprenden y procedimientos de preparacion de los mismos
CL2008000806A1 (es) Compuestos derivados de aza piridopirimidinona, con actividad agonista de hm74a; procedimiento de preparacion de dichos compuestos; composicion farmaceutico que las comprende; y su uso para preparar medicamentos para el tratamiento de enferemedades ateroscleroticas, dislipidemias, alzheimer, diabetes, entre otras.
BR112013004756A2 (pt) uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
WO2007062186A3 (en) Methods of using small molecule compounds for neuroprotection
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2007087292A3 (en) Mapc treatment of brain injuries and diseases
BRPI0607562A2 (pt) derivados da diosmetina para o tratamento e a prevenção das patologias trombóticas
PT1864668E (pt) Utilização de pró-fármacos para administração ocular intravítrea
CL2007002643A1 (es) Compuestos derivados de 5-fenil-nicotinamida, moduladores del receptor de cb1; procedimiento de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de trastornos de la nutricion, diabetes tipo ii y dependencia de sustan
BRPI0511209A (pt) composição farmacêutica e uso de uma associação de propionato de clobetasol e de calcitriol
BRPI0603762A (pt) uso de agomelatina para obtenção de medicamentos intencionados para o tratamento de distúrbios de sono em pacientes deprimidos
ES1062692Y (es) Dispositivo para la articulacion de asas en asientos infantiles, capazos-cuna y analogos
BRPI0509861A (pt) uso de simeticona em pacientes constipados
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
MY148092A (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease
UA97440C2 (en) Use of s-adenosylmethionine (sam) and superoxide dismutase (sod) for the preparation of medicaments for the treatment of alzheimer's disease
WO2008144690A3 (en) Compositions and methods for enhancing active agent absorption

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: PROTEXEON LIMITED (GB)

B25A Requested transfer of rights approved

Owner name: IMPERIAL INNOVATIONS LIMITED (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements